以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 北京市春立正达医疗器械股份有限公司是一家主要从事植入性骨科医疗器械研发、生产及销售业务的中 国公司。该公司主要产品包括关节假体产品、脊柱类植入产品、创伤类产品、运动医学类产品、富血小 板血浆（PRP）产品、口腔类产品、手术机器人产品。关节假体产品涵盖髋、膝、肩、肘四大人体关 节。该公司产品销往国内外市场。 证券之星消息，2月10日南向资金减持3.1万股春立医疗（01858.HK）。近5个交易日中，获南向资金减 持的有4天，累计净减持78.95万股。近20个交易日中，获南向资金减持的有11天，累计净减持90.12万 股。截至目前，南向资金持有春立医疗（01858.HK）4144.63万股，占公司已发行普通股的43.55%。 ...

Core Viewpoint - The orthopedic industry is facing scrutiny due to commercial bribery cases, while major companies are reporting significant revenue and profit growth for 2025, highlighting a contrast between industry recovery and ongoing issues of high sales expenses and unethical practices [2][6][8]. Group 1: Bribery Cases and Industry Impact - The National Healthcare Security Administration has reported significant bribery cases in the orthopedic field, with kickback rates reaching up to 40% [2][3]. - In a case involving a hospital director, illegal kickbacks totaled 2.72 million yuan, with a supplier paying 35% of the total supply as a monthly kickback [4]. - Another case revealed a hospital official receiving 3.66 million yuan in bribes over ten years, with kickback rates between 20% and 40% for various orthopedic devices [5]. Group 2: Financial Performance of Companies - Major orthopedic companies like Spring Medical, Dabo Medical, and Kelly Tai are forecasting significant revenue and profit increases for 2025, with some companies expecting profit growth exceeding 300% [2][6][7]. - The orthopedic consumables sector saw a 17% year-on-year revenue growth in the first three quarters of 2025, with net profit increasing by 81% [6][16]. - Spring Medical anticipates a net profit of 245 to 288 million yuan for 2025, representing a year-on-year increase of 96.01% to 130.41% [6][16]. Group 3: Sales Expenses and Challenges - Despite positive financial forecasts, high sales expenses remain a significant concern, with some companies' sales expense ratios exceeding the industry average [8][18]. - For instance, Dabo Medical's sales expense ratio was approximately 26.7%, indicating elevated marketing costs within the orthopedic sector [18]. - The ongoing high sales expenses are squeezing companies' research and development budgets, with reductions in R&D spending reported by several firms [19].

来源：新浪证券-红岸工作室 2月9日，春立医疗跌0.35%，成交额3498.88万元。两融数据显示，当日春立医疗获融资买入额524.38万 元，融资偿还376.73万元，融资净买入147.65万元。截至2月9日，春立医疗融资融券余额合计4854.82万 元。 融资方面，春立医疗当日融资买入524.38万元。当前融资余额4852.98万元，占流通市值的0.73%，融资 余额超过近一年90%分位水平，处于高位。 资料显示，北京市春立正达医疗器械股份有限公司位于北京市通州区通州经济开发区南区鑫觅西二路10 号，成立日期1998年2月12日，上市日期2021年12月30日，公司主营业务涉及北京市春立正达医疗器械 股份有限公司是一家主要从事植入性骨科医疗器械研发、生产及销售业务的中国公司。该公司主要产品 为关节假体产品及脊柱类植入产品。关节假体产品涵盖髋、膝、肩、肘四大人体关节。脊柱类植入产品 为脊柱内固定系统的全系列产品组合。该公司的产品出口至亚洲、南美洲、非洲、大洋洲及欧洲等多个 国家和地区。主营业务收入构成为：医疗器械产品99.89%，其他(补充)0.11%。 截至9月30日，春立医疗股东户数6164.00，较上 ...

证券之星消息，截至2026年2月9日收盘，春立医疗(688236)报收于23.0元，下跌0.35%，换手率0.53%， 成交量1.52万手，成交额3498.88万元。 2月9日的资金流向数据方面，主力资金净流出63.27万元，占总成交额1.81%，游资资金净流入391.14万 元，占总成交额11.18%，散户资金净流出327.87万元，占总成交额9.37%。 春立医疗融资融券信息显示，融资方面，当日融资买入524.38万元，融资偿还376.73万元，融资净买入 147.65万元。融券方面，融券卖出400.0股，融券偿还0.0股，融券余量800.0股，融券余额1.84万元。融 资融券余额4854.82万元。 近5日融资融券数据一览见下表： | 日期 | 涨跌幅 | | 融资余额(元) 融资净买入(元) 融券余量(股) | | (品)用品要求量 | 融资融券余额(元) | | --- | --- | --- | --- | --- | --- | --- | | 2026-02-09 | -0.35% | 4852.98万 | 147.65万 | 800.0 | 400.0 | 4854.82万 | | 2026 ...

北京市春立正达医疗器械股份有限公司是一家主要从事植入性骨科医疗器械研发、生产及销售业务的中 国公司。该公司主要产品包括关节假体产品、脊柱类植入产品、创伤类产品、运动医学类产品、富血小 板血浆（PRP）产品、口腔类产品、手术机器人产品。关节假体产品涵盖髋、膝、肩、肘四大人体关 节。该公司产品销往国内外市场。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，2月9日南向资金增持1.27万股春立医疗（01858.HK）。近5个交易日中，获南向资金减 持的有3天，累计净减持67.4万股。近20个交易日中，获南向资金减持的有10天，累计净减持76.9万股。 截至目前，南向资金持有春立医疗（01858.HK）4147.73万股，占公司已发行普通股的43.59%。 ...

Core Viewpoint - Spring Medical, a leading domestic orthopedic medical device manufacturer, focuses on the research, production, and sales of implantable orthopedic medical devices, including dental metal and invisible orthodontics, and is currently in the design and inspection phase for customized porous tantalum dental implants [2][3]. Company Overview - Spring Medical is located in Tongzhou District, Beijing, and was established on February 12, 1998. The company went public on December 30, 2021, and primarily engages in the research, production, and sales of implantable orthopedic medical devices [7]. - The main products include joint prosthetics and spinal implant products, covering four major human joints: hip, knee, shoulder, and elbow, as well as a full range of spinal internal fixation systems [8]. Financial Performance - For the period from January to September 2025, Spring Medical achieved operating revenue of 756 million yuan, representing a year-on-year growth of 48.75%, and a net profit attributable to shareholders of 192 million yuan, with a year-on-year increase of 213.21% [8]. - The company has distributed a total of 440 million yuan in dividends since its A-share listing, with 390 million yuan distributed over the past three years [8]. Industry Position - Spring Medical has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which is the highest honor for small and medium-sized enterprises in China, indicating strong innovation capabilities and high market share [3]. - The company is classified under the pharmaceutical and biological industry, specifically in medical devices and consumables, and is involved in various concept sectors including dental medical, robotics, and innovative enterprises [8]. Shareholder Information - As of September 30, 2025, the top ten circulating shareholders include Hong Kong Central Clearing Limited as the fourth largest shareholder with 2.9585 million shares, and new entrants such as China Europe Economic Selection Mixed A and Ping An Low Carbon Economy Mixed A [9].

证券日报网讯2月6日，春立医疗在互动平台回答投资者提问时表示，国际化战略是公司发展的核心驱动 力之一。公司积极推进海外市场布局。目前，公司产品已销往全球多个国家和地区，其中包括欧盟成员 国。 ...

来源：新浪证券-红岸工作室 截至9月30日，春立医疗股东户数6164.00，较上期增加4.12%；人均流通股46906股，较上期减少 3.95%。2025年1月-9月，春立医疗实现营业收入7.56亿元，同比增长48.75%；归母净利润1.92亿元，同 比增长213.21%。 分红方面，春立医疗A股上市后累计派现4.40亿元。近三年，累计派现3.90亿元。 机构持仓方面，截止2025年9月30日，春立医疗十大流通股东中，香港中央结算有限公司位居第四大流 通股东，持股295.85万股，为新进股东。中欧景气精选混合A（020876）位居第五大流通股东，持股 283.26万股，为新进股东。平安低碳经济混合A（009878）位居第八大流通股东，持股210.00万股，相 比上期减少167.00万股。南方医药保健灵活配置混合A（000452）退出十大流通股东之列。 声明：市场有风险，投资需谨慎。本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本文 出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 2月5日，春立医疗涨0.43%，成交 ...

Core Viewpoint - Spring Medical, a leading domestic orthopedic medical device manufacturer, focuses on the research, production, and sales of implantable orthopedic medical devices, including dental metal and invisible orthodontics, and is currently in the design and inspection phase for a customized porous tantalum dental implant product [2][3]. Company Overview - Spring Medical is located in Tongzhou District, Beijing, and was established on February 12, 1998. The company went public on December 30, 2021, and primarily engages in the research, production, and sales of implantable orthopedic medical devices [7][8]. - The main products include joint prosthetics and spinal implant products, covering four major human joints: hip, knee, shoulder, and elbow, as well as a full range of spinal internal fixation systems [8]. Financial Performance - For the period from January to September 2025, Spring Medical achieved operating revenue of 756 million yuan, representing a year-on-year growth of 48.75%, and a net profit attributable to shareholders of 192 million yuan, with a year-on-year increase of 213.21% [8]. - Since its A-share listing, the company has distributed a total of 440 million yuan in dividends, with 390 million yuan distributed over the past three years [8]. Market Position and Recognition - The company has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which is the highest honor for small and medium-sized enterprises in China, indicating strong innovation capabilities and high market share [3]. - Spring Medical's products are exported to various regions, including Asia, South America, Africa, Oceania, and Europe, with its main business revenue composition being 99.89% from medical device products [8]. Shareholder Information - As of September 30, 2025, the number of shareholders in Spring Medical was 6,164, an increase of 4.12% from the previous period, with an average of 46,906 circulating shares per person, a decrease of 3.95% [8][9]. - Notable institutional shareholders include Hong Kong Central Clearing Limited and China Europe Economic Growth Fund, both of which are new entrants among the top ten circulating shareholders [9].

北京市春立正达医疗器械股份有限公司是一家主要从事植入性骨科医疗器械研发、生产及销售业务的中 国公司。该公司主要产品包括关节假体产品、脊柱类植入产品、创伤类产品、运动医学类产品、富血小 板血浆（PRP）产品、口腔类产品、手术机器人产品。关节假体产品涵盖髋、膝、肩、肘四大人体关 节。该公司产品销往国内外市场。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 | 交易日 | 持股总数 (股) | 持股变动(股) | 变动幅度 | | --- | --- | --- | --- | | 2026-02-05 | 4167.83万 | -15.38万 | -0.37% | | 2026-02-04 | 4183.21万 | -40.38万 | -0.96% | | 2026-02-03 | 4223.58万 | 8.45万 | 0.20% | | 2026-02-02 | 4215.13万 | 7.40万 | 0.18% | | 2026-01-30 | 4207.73万 | -2.83万 | -0.07% | 证券之星消息，2月5日南向资金 ...